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Purpose: To study resistance-associated substitutions using next-generation sequencing in
Egyptian hepatitis C virus-infected patients failing direct-acting antiviral treatment.
Methods: The current study describes three cases of treatment failure in patients referred to
Zagazig Viral Hepatitis Treatment Center (ZVHTC), Sharkia Governorate, Egypt. RAS were
identified and characterized using deep sequencing. The first patient had breakthrough while
receiving a daclatasvir (DCV)+sofosbuvir (SOF) regimen, patient 2 relapsed after treatment
with DCV+SOF+ribavirin (RBV), and patient 3 relapsed after DCV+SOF therapy. A serum
sample was collected from each patient at failure and sent to Vall d’Hebron Research
Institute at Hospital Universitari Vall d’Hebron in Barcelona (Spain) for deep-sequencing
study to identify and characterize the RAS present in the samples.
Results: The following were identified: L28M, L30S and L28M+L30S in patient 1, L30R in
patient 2, and R155C, D168E, L28M, L30H, L30S, L28M+L30H, and L28M+L30S in
patient 3.
Conclusion: To the best of our knowledge, this is the first report from Egypt of patients
failing DAA-based therapy, describing the associated RAS. This information will be of help
to understand the natural history of HCV in Egyptian patients and guide the proper choice of
retreatment protocols.
Keywords: resistance-associated substitutions, RAS, subtype 4a, treatment failure, Egypt,
direct acting antivirals, DAA
Introduction
Egypt has one of the highest prevalence rates of hepatitis C virus (HCV) infection
worldwide. In 2008, the Egypt Demographic and Health Survey (EDHS) reported
that nearly 10 million Egyptians were infected with this virus, whereas the 2015
EDHS identified a clear decline, reporting chronic HCV infection in only 6 million
individuals.1 Nonetheless, this is a large number of cases, and it indicates that HCV
remains a serious national health problem.2 A systematic review of HCV genotypes
has reported limited diversity in Egypt, with dominance of genotype (GT) 4,
accounting for 92.5% of cases (12.1% subtype 4a and 82.3% unknown subtypes),
followed by 3.6% of GT1 cases, and 3.2% of mixed infections.3
It has become clear that the root causes for this high prevalence (4.5–6.7%) are
strongly associated with poor compliance with infection prevention and control in
both the hospital and community settings.4 In 2006, the Egyptian National
Committee for Control of Viral Hepatitis (NCCVH) was established to set up and
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implement a national HCV control program. One of the
Committee’s strategies was to provide affordable and
accessible treatment, based at that time on pegylated inter-
feron/RBV. In 2014, after successful negotiation between
Gilead and the Egyptian Government represented by the
NCCVH, the first direct-acting antiviral (DAA) drug,
sofosbuvir (SOF) was introduced. Treatment regimens
using this agent led to a sustained virological response
(SVR) rate of 90%. In 2015 to 2016, new combinations
were approved in Egypt to improve antiviral treatment and
cover all patients chronically infected with HCV.5 The
HCV program is continuously updated to open the pro-
spect of future elimination of the disease in Egypt.
Real-life studies using DAA-based regimens in the
Egyptian population have reported very few cases of the
breakthrough and relapse categories of treatment failure.
In this study, we report on 3 HCV subtype 4a-infected
Egyptian patients who failed to respond to regimens of
daclatasvir (DCV) + SOF with/without RBV. A RAS study
was performed using deep-sequencing to investigate the
patients’ RAS profile in targeted and non-targeted regions
of the HCV proteins, NS3, NS5A, and NS5B.
Materials and methods
Patient samples
The original three serum samples were from HCV-infected
patients who had failed DAA-based antiviral treatments in
the Zagazig Viral Hepatitis Treatment Center (ZVHTC),
Sharkia Governorate, Egypt. The study was approved by
ZVHTC and the three patients signed an informed consent
for participation. The RAS analysis was approved by the
clinical research ethic committee of Hospital Universitari
Vall d’Hebron. To perform the study of resistance-asso-
ciated substitutions (RAS), one sample from each patient
taken during 2018 at the time of failure was delivered on
dry ice to Vall d’Hebron Research Institute at Hospital
Universitari Vall d’Hebron (VHIR-HUVH) in Barcelona,
for characterization using a next-generation sequencing
(NGS) technique adapted to the MiSeq platform.
Definitions
For the present study, HCV viral breakthrough was defined
as an increase in viral load at the end of antiviral treat-
ment, even though HCV RNA had been undetectable dur-
ing the treatment period. Viral relapse was defined as
confirmed detectable HCV RNA levels during the post-
treatment follow-up period in patients who had an unde-
tectable HCV RNA level at the end of treatment.
Patient 1
Patient 1 was a 65-year-old diabetic woman with hyper-
tension. She was receiving gliclazide and metformin to
manage diabetes mellitus, and amlodipine and torsemide
for hypertension. On ultrasound study, her gall bladder
showed a thickened wall and internal calculi. There was
no ascites, but splenomegaly was visualized (16.7 cm,
superior to inferior axis). The superior mesenteric vein
and splenic vein were enlarged (>10 mm), and the dia-
meter of the portal vein was 13 mm. The portal venous
flow was slow (<15 cm/sec), and showed reversal or to-
and-fro flow. The patient was diagnosed with compensated
liver cirrhosis and splenomegaly. Her condition was clas-
sified as Child Class A, with a Child Pugh (CP) score of 5
and MELD score of 9. The signs of liver cirrhosis included
the following: surface nodularity, a generally coarse echo-
texture, segmental atrophy, caudate width:right lobe width
ratio >0.65, and a reduction (<30 mm) in the transverse
diameter of the medial segment (segment IV) of the left
lobe. The body mass index (BMI) was 26.4, hemoglobin
measured 13.3 g/dL, platelet count was 120×109/L, and
total leucocyte count was 4.8×109/L. The international
normalized ratio (INR) was 1.23. Serum albumin, total
bilirubin, alanine transaminase (ALT), and aspartate trans-
aminase (AST) levels were 3.9 g/dL, 0.91 mg/dL, 95 U/L,
and 165 U/L, respectively. Alpha fetoprotein (AFP) con-
centration was 16 ng/mL, antinuclear antibodies (ANA)
tested negative, and serum creatinine was 0.6 mg/dL.
On virological testing, HBsAg was negative and the
virus was identified as HCV genotype 4a (G4a). HCV viral
load in serum was 1,959,000 IU/mL, as determined by the
TaqMan Real Time PCR assay (Roche Applied Science,
Basel, Switzerland), which had a lower limit of detection
of 15 I U/mL.
The patient had never received antiviral treatment
(naïve) and was cirrhotic. She was referred to ZVHTC
for treatment and was prescribed SOF (400 mg daily)
plus DCV (60 mg daily) for 12 weeks (12 W), reporting
good treatment adherence.
On HCV RNA monitoring at week 4 (4 W) of treat-
ment, the virus was undetectable. At 12 W, the end of
treatment (EOT), HCV RNA measured 393 IU/mL and at
12 weeks follow-up after stopping therapy (12 WFU),
HCV RNA level was 707,999 IU/mL. The patient was
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retreated with SOF/DCV/RBV for 24 weeks and
attained SVR.
Patient 2
Patient 2 was a 48-year-old man with a diagnosis of HCV
cirrhosis and a history of liver encephalopathy attacks. He
was referred to ZVHTC for treatment. The patient was
treatment-experienced and had failed a 6-month course of
SOF+RBV.
Ultrasonography showed an enlarged spleen (18 cm,
superior to inferior axis), portal vein diameter of 11 mm,
and signs of hepatic cirrhosis (surface nodularity, overall
coarse and heterogeneous echotexture, segmental hyper-
trophy/atrophy, caudate width:right lobe width ratio >0.65,
and a reduction in the transverse diameter (<30 mm) of
segment IVof the left lobe. The BMI was 36.3. Blood tests
showed a hemoglobin level of 13.6 g/dL, platelet count
88×109/L, and total leucocyte count 2.7×109/L. The INR
was 1.28. Liver function tests yielded the following
results: serum albumin 3.7 g/dL, total bilirubin 0.84 mg/
dL, ALT 174 U/L, and AST 168 U/L. AFP measured
22 ng/mL, ANA tested negative, and serum creatinine
was 0.93 mg/dL. The patient received a diagnosis of portal
hypertension with splenomegaly and was classified as
Child Class A, with a CP score of 6 and MELD Score of 9
On virological testing, HBsAg was negative and the
virus was identified as HCV G4a. Prior to designing a
second therapy, serum HCV viral load, measured with
the same real-time PCR method described above, was
found to be 725,245 IU/mL.
The patient was prescribed SOF (400 mg daily) plus
DCV (60 mg daily) plus RBV (600–1000 mg daily, with
dose adjustment according to tolerability) for 24 weeks.
The patient reported good treatment adherence.
HCV Monitoring at 4 W, 12 W, and 16 W during
treatment, 24W EOT, and 12 W after EOT (12 WFU)
yielded the following viral load data: 132 IU/mL, unde-
tectable viral load, undetectable viral load, undetectable
viral load, and 865,000 IU/mL, respectively. The patient,
who was diagnosed as having a relapse, ultimately died
because of deteriorating liver function.
Patient 3
Patient 3 was a 58-year-old diabetic man receiving Humalog
insulin. He had mild ascites. Ultrasonography showed an
enlarged spleen (15.7 cm, superior to inferior axis), portal
vein diameter of 14 mm, and signs of hepatic cirrhosis,
including surface nodularity, overall coarse and
heterogeneous echotexture, segmental hypertrophy/atrophy,
caudate width:right lobe width ratio >0.65, and a reduction in
the transverse diameter (<30 mm) of segment IV of the left
lobe. The BMI was 29.5. Blood tests showed a hemoglobin
level of 9.6 g/dL, platelet count 52×109/L, and total leucocyte
count 1.4×109/L. The INR was 1.3. Liver function tests
yielded the following results: serum albumin 2.5 g/dL, total
bilirubin 1.8 mg/dL, ALT 35 U/L, and AST 73 U/L. AFP
concentration was 9 ng/mL, ANA tested negative, and serum
creatinine was 1 mg/dL. The patient was diagnosed as having
decompensated cirrhosis, portal hypertension, splenomegaly,
and mild ascites, and was classified as Child Class B, with a
CP score of 8 and MELD score of 12.
On virological testing, HBsAg was negative and the
virus was identified as HCV G4a. Prior to the start of
retreatment, serum HCV viral load, measured with the
same real-time PCR method described above, was found
to be 9,285,197 IU/mL.
The patient had never received antiviral treatment
(naïve). At ZVHTC he was prescribed SOF (400 mg
daily) plus DCV (60 mg daily) plus RBV (600–1000 mg,
with dose adjustments according to tolerability) for
12 weeks. He reported good treatment adherence.
HCV-RNA was monitored at 4 W, 12 W EOT, and 12
and 24 W follow-up after stopping therapy (12 and
24 WFU). On RT-PCR monitoring, HCV RNA was unde-
tectable at 4 W, 12 W EOT, and 12 WFU. At 24 WFU,
viral load was 402,020 IU/mL. He was diagnosed as hav-
ing HCV relapse.
The patient’s clinical condition worsened, with recur-
rent attacks of hepatic encephalopathy, increasing ascites,
and development of hepatic hydrothorax. The patient
could not afford the cost of a liver transplantation. He
has not been retreated and is currently under conservative
treatment for liver failure.
Methods
A serum sample was collected from each patient at treatment
failure and sent to Vall d’Hebron Research Institute at
Hospital Universitari Vall d’Hebron (VHIR-HUVH,
Barcelona) for deep-sequencing study. HCV RNA was
obtained from 140 µL of serum by manual extraction using
the QIAmp Viral RNA Mini Kit (Qiagen, Hilden, Germany)
following the manufacturers’ instructions and avoiding
contamination.6 A high-resolution HCV subtyping method
was used to identify HCV subtype and mixed infections
(infection with more than one subtype at the same time).7
The HCVNS3, NS5A and NS5B regions, which are targeted
Dovepress Amer et al
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by DAAs, were amplified by RT-PCR-Nested using G4a-
specific primers (Table 1).8 Reverse transcription and the first
round of PCR amplification were performed with the
Transcriptor One-Step RT-PCR Kit (Roche Diagnostics,
Mannheim, Germany), using an annealing temperature of
55 ºC and 40 seconds of elongation during 35 cycles. The
KAPA HiFi HotStart PCR Kit (KAPA Biosystems,
Wilmington, Massachusetts, USA) was used for nested
amplification, applying an annealing temperature of 55 ºC
and elongation time of 15 seconds for a total of 30 cycles.
The KAPA Library Preparation Kit for Illumina Platforms
(KAPA Biosystems, Wilmington, Massachusetts, USA) was
used to prepare the DNA library, and the SeqCap Adapter Kit
A/B (Nimblegen, Roche,Mannheim, Germany) to label each
patient’s amplified product. KAPA Pure Beads (KAPA
Biosystems, Wilmington, Massachusetts, USA) were used
at a 0.8:1 ratio for the purification steps. Deep sequencing on
the MiSeq (Illumina) platform was performed using the
MiSeq Reagent Kit v3 for 600 cycles (Illumina, San Diego,
California, USA).
An in-house R script was used to obtain RAS reports
from raw data after running the MiSeq in 2×300 mode.9
Additional details related to the RT-PCR-Nested amplifi-
cation and deep-sequencing methodology can be found in
a previous study.7
A bioinformatics haplotype-centric procedure was
developed to filter and exclude reads with lower quality
than a minimum requirement. The FLASH software pro-
gram was used to overlap paired-end reads, establishing a
minimum overlap between R1 and R2 of 20 bp, with a
maximum of 10% differences. A detailed description of
these steps can be found in the study by Soria et al.8
Because of the considerable intra-subtype diversity of
HCV, 1068 sequences were retrieved from the Los Alamos
databank to generate a consensus sequence (defined by the
most frequent amino acid at each position) for subtypes G1a,
G1b, G2c, G2i, G2j, G3a, G4a, and G4d to designate amino
acid changes. All the reported amino acid changes were
included in a final report, highlighting those changes that
have been described as resistance associated substitutions
compared to the G4a consensus sequence, but also including
all other changes found in this study (Figure 1 and Table 2).
Results
The NS3, NS5A and NS5B sequences from the three
patients have been deposited in the GenBank database
with accession number “PRJNA554981”. Ta
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At 4 weeks of DAA-based treatment, patients 1 and 3
showed an early positive antiviral response, whereas
patient 2 had a viral load of 132 IU/mL and continued
treatment for 24 weeks.
Patient 1 tested HCV RNA-positive at EOT (12 W),
with a value of 393 IU/mL, suggesting viral breakthrough.
At 12 WFU, viral load had increased to 707,999 IU/mL. In
the case of patient 2, HCV-RNAwas undetectable at 12 W
and 16 W during treatment, and at 24 W EOT. At
12 WFU, viral load was 865,000 IU/mL, reflecting viral
relapse. Patient 3 had undetectable HCV-RNA at 12 W
EOT, but 24 weeks later HCV relapsed to 402,020 IU/mL.
All 3 patients were infected by G4a. No other subtypes
were observed (no mixed infections).
The first and third patients failed DCV+SOF treat-
ment. The second patient failed combination therapy
with these two agents plus RBV. Deep-sequencing ana-
lysis was performed on the NS3, NS5A, and NS5B
regions. Coverage (number of reads sequenced per
amplicon) was between 26,160 and 66,949 reads per
region per patient (Table 2).
RAS appeared in the NS5A region at residues 30 and/
or 28 in all patients (Table 2). In 2 patients (patients 1 and
3), all viral genomes carried the L28M substitution, and in
most genomes, this substitution was combined with L30S
(Table 2A and C). Additionally, in patient 3, 12.1% of
reads showed the L28M+L30H combination (Table 2C).
RAS in residues 28 and 30 cause resistance to DCV,
elbasvir, and ledipasvir. Moreover, RAS combination pat-
terns in the same viral particle cause dramatically
increased resistance to the inhibitor used in the failed
treatment and in other inhibitors of the same family. For
example, L28M+L30H cause a mean-fold resistance of
10,000 to ledipasvir (Table 2C). In patient 2, who had
received RBV, the L30R RAS was observed alone
(Table 2B), conferring resistance to DCV and velpatasvir.
Interestingly, deep-sequencing study showed two
RAS (R155C and D168E) at very low frequencies
(1.3% and 1.5%, respectively) in the non-targeted NS3
region in patient 3. R155C causes resistance to gleca-
previr and paritaprevir, whereas D168E is associated
with resistance to voxilaprevir, simeprevir, and parita-
previr (Table 2C). We also observed the minority sub-
stitution K24R (1.9%), which confers ledipasvir
resistance in HCV G1a,10,11 but has an unknown RAS
effect in G4a.
No RAS were observed in the NS5B region in any
patient. However, alignment of the patients’ sequences
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I303V 44880
63756
17832
63196
19953
63756 100.0
100.0
70.4
31.3
99.1
28.0
NSS8
L30S
C57R
K107E
D126E
V130I
NS3
NSSA
K92R
A101S
T122A
Region Variants Frequencies (%)
Region Variants Frequencies (%)
Region Variants Frequencies (%)
Region Variants Frequencies (%)
Region Variants Frequencies (%)
Region Variants Frequencies (%)
Region Variants Frequencies (%)
Region Variants Frequencies (%)
Region Variants Frequencies (%)
Figure 1 Amino acid substitutions found in samples from patients 1, 2, and 3 in the three HCV antiviral target regions, NS3, NS5A, and NS5B, compared to a subtype 4a
consensus sequence retrieved from Los Alamos databank. For each patient and region we report (in columns) the region, the amino acid change, the number of reads
(sequences) obtained, and the frequency of each substitution in the total reads obtained. Total reads: Patient 1, NS3 (58,871 reads), NS5A (59,492), and NS5B (63,756);
Patient 2, NS3 (66,949); NS5A (26,160), and NS5B (32,337); Patient 3, NS3 (56,665), NS5A (58,493), and NS5B (36,253).
Abbreviation: HCV, Hepatitis C virus.
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with the consensus G4a sequence, composed of isolates
downloaded from the Los Alamos database, identified two
NS5B amino acid substitutions (A235V/T, R304K) with
an unknown RAS effect. Specifically, all three patients
were carrying the A235V substitution in almost all reads
(99.3–100%), whereas R304K, reported at baseline in
Portuguese G4a patients,12 was prevalent in patient 3.
Amino acid substitutions in patients 1, 2, and 3 in the
three HCV antiviral target regions (NS3, NS5A, NS5B)
compared to a subtype 4a consensus sequence retrieved
from the Los Alamos databank are shown in Figure 1. For
each patient and region we report (in columns) the region,
the amino acid change, the number of reads (sequences)
obtained, and the frequency of each substitution among the
Table 2 Individual RAS and RAS combinations found in samples from patient 1 (Table 2A), patient 2 (Table 2B), and patient 3 (Table
2C). The tables show the frequency at which each substitution was observed (after passing the filter) in the total number of reads
obtained for each region, and the mean fold-change in resistance compared to the wild type. Underlined values indicate the reported
mean fold-change in resistance for the substitution independently of the wild-type amino acid
Table 2A. Patient 1. Mean fold-change in resistance to DAAs of each RAS identified
Region (Total Reads) RAS (Frequency %) ASV GLE GZR PTV SMV MK-7009 VOXI
NS3 (58,871) NO RAS IDENTIFIED IN THIS REGION
DCV EBR LDV OMV PIB VEL
L28M (100.0) 10 n.d. 100
NS5A (59,492) L30S (99.6) 150–157 4 100
L28M+L30S (99.6) 5000
SOF DSV
NS5B (63,756) NO RAS IDENTIFIED IN THIS REGION
Table 2B. Patient 2. Mean fold-change in resistance to DAAs of each RAS identified
Region (Total Reads) RAS (Frequency %) ASV GLE GZR PTV SMV MK-7009 VOXI
NS3 (66,949) NO RAS IDENTIFIED IN THIS REGION
DCV EBR LDV OMV PIB VEL
NS5A (26,160) L30R (100.0) 10 2
SOF DSV
NS5B (32,337) NO RAS IDENTIFIED IN THIS REGION
Table 2C. Patient 3. Mean fold-change in resistance to DAAs of each RAS identified
Region (Total Reads) RAS (Frequency %) ASV GLE GZR PTV SMV MK-7009 VOXI
NS3 (56,665) R155C (1.3) 2.6 59
D168E (1.5) n.d. n.d. 2.5–20
DCV EBR LDV OMV PIB VEL
L28M (100.0) 10 n.d. 100
L30H (12.1) 155–1215 n.d. n.d.
NS5A (58,493) L30S (87.9) 150–157 4 100
L28M+L30H (12.1) 64 10,000
L28M+L30S (87.9) 5000
SOF DSV
NS5B (36,253) NO RAS IDENTIFIED IN THIS REGION
Notes: n.d. = described as resistant but with no data; empty box indicates no resistance.
Abbreviations: ASV, asunaprevir; DAA, direct-acting antiviral; DCV, daclatasvir; DSV; dasabuvir; EBR, elbasvir; GLE, glecaprevir; GZR, grazoprevir; LDV, ledipasvir; MK-
7009, vaniprevir; OMV, ombitasvir; PIB, pibrentasvir; PTV, paritaprevir; RAS, resistance-associated substitutions; SMV, simeprevir; SOF, sofosbuvir, VEL, velpatasvir; VOXI,
voxilaprevir.
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total reads obtained: patient 1, NS3 (58,871 reads in total),
NS5A (59,492), and NS5B (63,756); patient 2, NS3
(66,949), NS5A (26,160), and NS5B (32,337); and patient
3, NS3 (56,665), NS5A (58,493), and NS5B (36,253).
Discussion
The recent introduction of DAA therapy has revolutio-
nized the treatment of chronic HCV infection in several
countries worldwide, including Egypt, with very high SVR
rates in clinical trials and slightly lower rates in real-life
cohorts.13 The emergence of HCV resistance variants (ie,
RAS), is the main reason for this difference, but little
information on resistance in G4a patients has been
reported, as most studies include only a small number of
patients with this subtype, and very few have been done
using deep-sequencing.10,11,14,15 In this study, we report
the RAS profile determined by this technique in Egyptian
patients failing DAA-based treatments.
All samples were analyzed for RAS in the NS3, NS5A
and NS5B proteins by deep-sequencing using the MiSeq
(Illumina) platform. The rationale to study all three DAA-
targeted regions was that extra-target mutations and hitch-
hiking mutations can be selected at failure and negatively
impact salvage treatments. In this sense, two minority
RAS (R155C and D168E) in the non-targeted NS3 region
were observed in patient 3 at very low frequencies (1.3%
and 1.5%, respectively) (Table 2C). Neither of these min-
ority RAS would have been detected using population
(Sanger) sequencing, and both of them could have reduced
retreatment options.14,16 R155C causes resistance to gle-
caprevir and paritaprevir, whereas D168E confers resis-
tance to voxilaprevir, simeprevir, and paritaprevir.10,11
The level of resistance to an inhibitor depends on
several conditions: the genetic barrier to resistance of the
HCV region, the drug used, the type of RAS, the fre-
quency at which RAS are present in the viral isolate, and
the presence of RAS combinations in the same viral par-
ticle, all of which can significantly increase resistance to
some DAA treatments. RAS combinations in the same
genome have been shown to cause a dramatic increase in
resistance to the inhibitor used in the failed treatment and
to other inhibitors of the same family.17 For example,
L28M+L30H causes a mean-fold resistance of 10,000 to
ledipasvir (Table 2C).
Our results show that L30R appeared alone in a patient
who had received RBV, whereas other L30 substitutions seem
to require combination with L28 mutations.16 This observa-
tion should be confirmed in additional patients to know
whether it is an occasional finding or the rule. A deep-sequen-
cing study in a large cohort of patients treated with and with-
out RBV has just been completed, and this molecule did not
have an influence on the type or number of RAS at HCV
treatment failure (data not shown, paper in preparation).
Coinciding with the results of a previous study16 the
L28M and L30 substitutions were the main RAS in G4a.
However, in contrast to that same study18 in which L30Rwas
the majority substitution, L30S was the most prevalent in our
patients. The RAS pattern in G4a was completely different
from that of G4d, the most prevalent G4 subtype in Spain, in
which the most common RAS was T58P (data not shown,
paper in preparation). Moreover, NS5A polymorphisms at
Y93 (Y93H/S/T) were not identified in the 3 patients failing
therapy, in agreement with previous studies.11,18 Additional
studies are needed to demonstrate whether or not A235V/T
and R304K in the NS5B protein and K24R in NS5A are
resistant to the inhibitors. Other highly prevalent substitu-
tions observed in our study, such as A150V in NS3,19 V52I,
T75I, V99I, I101V,20 N105S, F108R/C, V124A, D126E,21
and V130I,20 in NS5A, and N130D, P135V, A190S,
E202D,20 V228I, E237A, E248D, and T254A in NS5B
should still be considered simple polymorphic substitutions
without resistance implications, requiring further study. As
there are few studies on RAS emerging in patients failing
DAA treatment, more work is needed to determine whether
any newly described substitutions can be classified as RAS,
as adaptive mutations, or as random occurrences.
To our knowledge, this is the first study investigating
resistance-associated substitutions using next-generation
sequencing in Egyptian HCV-infected patients failing
DAA treatment. Deep sequencing-based studies of the
three antiviral targeted regions facilitate identification of
major and minor substitutions, the frequency at which
they are present in the viral isolate, and whether or not
they are combined with others in the same viral genome.
This information is useful for designing successful
retreatment strategies, and is of particular importance
in the absence of next-generation HCV treatments incor-
porating pangentotypic22 DAAs that will be effective in
Egypt and other parts of the world having a high GT4
burden. Until future pangenotypic DAAs become afford-
able, accessible, and easily provided, a scenario that
may not materialize for several years, precise identifica-
tion of RAS leading to treatment failure is of value for
better patient management, offering the possibility of
improved quality of life.
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In view of lack of facilities or very high cost of RAS
testing in Egyptian laboratories together with the huge
number of patients treated daily, the NCCVH recommends
empirical retreatment of patients who fail NS5A inhibitor-
based therapy with a combination of HCV multitargeted
drugs. Quadruple therapy with sofosbuvir, daclatasvir, and
simeprevir plus ribavirin (SOF/DCV/SMV/RBV) or sofos-
buvir, ombitasvir, paritaprevir, and ritonavir plus ribavirin
(SOF/OBV/PTV/r/RBV) for 12 weeks is recommended for
these patients, provided they have neither decompensated
liver function nor an estimated glomerular filtration rate
(eGFR) below 30 mL/min/1.73 m2 body surface area.23
The efficacy and safety of SOF/OBV/PTV/r/RBV quad-
ruple therapy has been assessed in chronic HCV GT4
patients failing DAA-based regimens in Egypt. SVR was
achieved in 97% (109/113) of patients with good toler-
ability and safety of the drug combination.23 The same
group of researchers conducted another study using SOF/
DCV/SMV/RBV in a similar cohort of Egyptian patients,
and reported similar efficacy (SVR 97%) and safety
results.24 However, the studies from Egypt are limited
and include relatively small patient samples. Efficacy and
safety analyses of data from the Egyptian NCCVT in
patients using these DAA combinations are needed. In
July 2017 the Food and Drug Administration (FDA)
approved a regimen consisting of a fixed-dose combina-
tion of sofosbuvir, velpatasvir and a second-generation
HCV-protease inhibitor, voxilaprevir, for retreatment of
HCV GT 1–6 after failure with sofosbuvir or other
NS5A inhibitors without RAS testing.25 Again, clinical
trials are needed to assess the efficacy and safety of
these new generations of DAAs in Egyptian patients.
Until these pangenotypic DAAs become affordable, acces-
sible, and easily provided in Egypt’s market based on
clinical proof of better safety and efficacy, a scenario that
may not materialize for several years, precise identification
of RAS leading to treatment failure is of value for better
patient management, providing the possibility of improved
quality of life.
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